Companies › PGEN
PRECIGEN (PGEN)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001356090 · EDGAR filings · Updated 2026-07-01
PRECIGEN (PGEN) has reported institutional ownership of 37.5%, with 205 institutional managers holding positions valued at $516.6M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-01 — Insider transaction reported (Form 4)
- 2026-07-01 — Insider transaction reported (Form 4)
- 2026-07-01 — Insider transaction reported (Form 4)
- 2026-07-01 — Notice of proposed sale filed (Form 144)
- 2026-06-29 — Notice of proposed sale filed (Form 144)
- 2026-06-29 — Notice of proposed sale filed (Form 144)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, PRECIGEN has 205 institutional holders and institutional ownership of 37.5%.
Insider activity
Insiders reported 71 transactions (7 buys, 31 sells) across 13 reporting insiders, with a net reported value of −$62.0M.
Data flags from SEC filings
Related companies
KAMADA LTD (KMDA) · ZAI LAB LTD (ZLAB) · MYRIAD GENETICS INC (MYGN) · BRIDGEBIO ONCOLOGY THERAPEUTIC (BBOT) · COMPASS PATHWAYS ADR A FUNSPONSORED ADR 1 ADR REPS 1 ORD SHS (CMPS) · MAPLIGHT THERAPEUTICS INC (MPLT)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-01.